A Novel CMY Variant Confers Transferable High-Level Resistance to Ceftazidime-Avibactam in Multidrug-Resistant Escherichiacoli

Junxin Zhou,Weiping Wang,Min Liang,Qian Yu,Shiqi Cai,Tailong Lei,Yan Jiang,Xiaoxing Du,Zhihui Zhou,Yunsong Yu

Microbiology Spectrum（2023）

引用 0|浏览1

暂无评分

摘要

Ceftazidime-avibactam is a novel β-lactam–β-lactamase inhibitor (BLBLI) combination with powerful activity against Enterobacterales isolates producing AmpC, such as CMY-like cephalosporinase. However, in recent years, CMY variants have been reported to confer ceftazidime-avibactam resistance.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要